Podcasts about circulating

There have been reported sightings of ICE agents across the North State on social media. But local organizations and law enforcement agencies report most are likely false alarms. Also, Chico State President Steve Perez sent a message to the campus community last week in response to worries about the school's fiscal situation amid a freeze on federal funding, and the second manual snow survey of the season measured 22 inches of snow depth, only 46 percent of average for the location near Echo Summit.

Do you know someone who is sick right now? There is a "Quademic" going around..  as referred to by health officials. 4 major viruses circulating in the US... Lois Collins with the Deseret News breaks down what you need to know about the viruses impacting Americans.

In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host for today's episode. Let's dive into a fascinating study published in JCO Precision Oncology entitled, “Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response.” This study led by Dr. Eric Michael Lander and colleagues examines a critical question: Can circulating tumor DNA help predict recurrence in patients with esophagogastric cancer who have achieved a favorable pathologic response after treatment? Esophagogastric cancer ranks as the seventh leading cause of cancer-related deaths worldwide. Despite aggressive treatment including neoadjuvant therapy followed by surgery, recurrence remains a grim reality for many patients. Interestingly, even those who achieve a pathologic complete response face a recurrence risk of up to 25%. This highlights a need for better tools to identify high-risk patients post-treatment. Circulating tumor DNA, or ctDNA for short, is emerging as a powerful biomarker in oncology. This minimally invasive blood-based test detects fragments of tumor DNA in the bloodstream, potentially signaling molecular residual disease before any radiographic evidence of recurrence appears. In this study, researchers focused on patients with locoregional esophagogastric cancer who had undergone neoadjuvant therapy followed by surgery, achieving either a complete or near complete pathologic response. Blood samples were collected postoperatively within a 16-week molecular residual disease window and during routine surveillance. The aim is to determine whether ctDNA positivity correlates with recurrence-free survival. The study analyzed 309 plasma samples from 42 patients across 11 institutions. Detectable ctDNA within the 16-week postoperative window was associated with a significantly higher recurrence risk. Among those with detectable ctDNA, 67% experienced recurrence compared to only 15% for those with undetectable ctDNA. This corresponds to a hazard ratio of 6.2, an alarming figure that underscores the potential for ctDNA as a prognostic tool. But the story doesn't end there. Postoperative surveillance ctDNA testing more than 16 weeks after surgery also proved to be a powerful prognostic indicator. Every patient with detectable ctDNA during surveillance eventually experienced recurrence, while only 7.4% of those with undetectable ctDNA relapse. These findings suggest that ctDNA testing could provide a critical lead time, enabling earlier interventions and personalized treatment strategies. Now let's talk about the clinical implications. Currently, patients who achieve a pathologic complete response often aren't considered for adjuvant therapies as the absence of visible disease is taken as a sign of remission. However, this study challenges that assumption. By integrating ctDNA testing into routine post-treatment surveillance, clinicians could identify high-risk patients who might benefit from additional therapy even when traditional imaging shows no signs of recurrence. This brings us to the bigger picture. Esophagogastric cancer treatment is evolving rapidly, with trials like CheckMate 577 and ESOPEC offering new insights into perioperative strategies. However, this study highlights a critical gap, the need for personalized, biomarker-driven approaches in the adjuvant setting. ctDNA could fill that gap, offering a non-invasive, dynamic way to monitor patients and guide clinical decisions. Of course, no study is without its limitations. The authors acknowledge the relatively small sample size and the retrospective nature of their analysis. They also note the variability in ctDNA testing and imaging schedules across institutions. However, the robust association between ctDNA positivity and recurrence-free survival makes a compelling case for further research in larger prospective cohorts. Looking ahead, what's the next step? The authors call for prospective validation of ctDNA as a prognostic tool, emphasizing its potential to refine risk stratification and optimize treatment strategies. Imagine a future where a simple blood test could dictate not only the need for additional therapies, but also the timing and type of intervention. As we wrap up, let's reflect on the broader impact of the study. By integrating ctDNA into routine cancer care, we could move closer to a world where treatments are not just effective, but also precisely tailored to each patient's unique biology and disease dynamics. Thank you for tuning into JCO Precision Oncology Article Insights. Don't forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. Until then, stay informed and stay inspired.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join our NEW Community Discord! https://www.discord.gg/podcast Today's topics we cover Epic's unforeseen job at handling cheaters. Topics: 1. Clix has his trio snake him in the final week! 2. Will the next LAN be in Raleigh or France? 3. Will Fortnite Competitive officially support the a new game mode? 4. Tune into the Comp awards! https://x.com/CompAwardsFN Follow Us On Twitter: MonsterDface - @MonsterDface Somebodysgun - @Somebodysgun LifeWithPanda - @LifewPanda  Email all of your complaints to us on twitter. Don't forget to leave us a comment!

This week on The Book Drop, we take a deeper look at the top circulating titles of 2024 for OPL, and discuss what they reveal about our community's awesome reading habits. This is The Book Drop.All the books and resources we talk about in this episode can be found at omahalibrary.org/podcast and here. Happening at the Library: Oregon Trail Live Action | Saturday, Jan. 18 | 1 to 3 p.m. | Saddlebrook Branch and Thursday, Jan. 23 | 6 to 7p.m. | Millard Branch Container Gardening Workshop | Tuesday, Jan. 21 | 10:30 to 11:30 a.m. | Swanson Branch Writer's Workshop | Tuesday, Jan. 21 | 5:30 to 7:30 p.m. | Benson Branch Explore all upcoming events at omahalibrary.org/events.

Circulating cell free DNA fragments are found in your bloodstream when cells die and release what's inside. Some of that DNA is your genetic material and some comes from mitochondria, the power plants of your cells. Johns Hopkins geriatrics expert … Are circulating DNA and inflammation related? Elizabeth Tracey reports Read More »

DNA fragments found in your blood, so called circulating cell free DNA, come from your cells as they die. Both genetic material and DNA from your energy plants, known as mitochondria, can be found, and both are implicated in increased … How does circulating DNA contribute to accelerated aging? Elizabeth Tracey reports Read More »

DNA fragments found circulating in an older person's blood are associated with frailty and Alzheimer's disease, studies by Peter Abadir, a geriatrics expert at Johns Hopkins, and colleagues have shown. These long term studies of several hundred older adults also … Higher levels of your own DNA circulating in your blood may be a problem, Elizabeth Tracey reports Read More »

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk and Dr. Riccardo Bertolo share highlights of the important kidney cancer developments for 2024. They summarise the results on several important trials such as FASTRACK, ZIRCON, KEYNOTE-564 and IMmotion010. They also discuss the developments on surgical aspects too.To learn more on the highlights discussed in this podcast, you can read the below Articles of the Month, listen to the podcasts or watch the videos.Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialASCO GU24 special: Assoc. Prof. Barata discusses the results of KEYNOTE-564 and CheckMate-914ASCO GU24 special: Prof. Michael Hofman talks about a novel CA IX-targeting peptideASCO2024 special: Circulating kidney injury molecule-1 biomarker analysis in IMmotion010Present and future of robotic surgery for RCCThe treatment of locally advanced and metastatic renal cancerFor more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, Google Podcasts.

See omnystudio.com/listener for privacy information.

Featuring an interview with Dr Seth Wander, including the following topics: ASCO Guidelines Rapid Recommendations Update for Testing for ESR1 Mutations (0:00) Real-world elacestrant use patterns and genomic biomarkers (4:43) Circulating tumor DNA (ctDNA) analyses with imlunestrant in the EMBER Phase I study (8:50) CME information and select publications

Liquid biopsies and circulating tumor DNA are changing and improving the way cancer is detected and treated. In this episode, Sameek Roychowdhury, PhD, MD, explains the basics of circulating tumor DNA, how it's being used at the James, his lab's clinical trials, and the promising future. “When a normal cell and a cancer die they sheds fragments of their DNA,” he said. “Cancer can be detected in the blood by looking for these fragments and this is becoming an important research tool and treatment tool for the care of cancer patients.” For example, about 50 percent of cancer patients who have a tumor surgically removed will have a recurrence. And it's very difficult to determine which patients will have the recurrence. Minimally invasive liquid biopsies after surgery “helps us stratify and determine patients with a lesser recurrence risk who won't need chemotherapy or immunotherapy treatment versus those patients who need even more treatment than we've normally given them in the past.” Monitoring circulating tumor DNA “also becomes part of the surveillance program and we'll do a precise test every three months that measures fragments in the blood,” Roychowdhury said, adding that finding a recurrence of cancer from these fragments, months before it would appear on more traditional scans “allows us to make a diagnosis about the molecular drivers of the cancer and we can begin treatment earlier and better understand which treatment options will work best.”

This week, Jonathan Sackier is joined by Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.  Timestamps:  (00:00) – Introduction  (02:00) – Carlos's favourite cuisine   (03:32) – Carlos's journey into oncology   (08:30) – The redefinition of breast cancer   (14:30) – How this taxonomy influences clinical care   (20:15) - Patient-derived xenografts for breast cancer   (28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden   (33:00) – Patient derived tumour cells for drug screening   (35:00) – Vitamin B5 and environmental factors in oncology   (38:44) – Current developments in breast cancer aetiology, diagnosis or treatment    (44:00) – The three wishes for the future of healthcare   (45:00) – Outro  

In this episode of the Gladden Longevity Podcast, Dr. Jeffrey Gladden and Steve Reiter discuss various aspects of health optimization, focusing on longevity, pregnancy health, and breast cancer awareness. They explore innovative therapies like ozone treatment and detoxification methods, as well as provide actionable recommendations for couples planning for pregnancy. The conversation also addresses common myths surrounding breast cancer, emphasizing the importance of genetics and regular screenings. In this episode, the conversation delves into various aspects of cancer detection, treatment, and overall health maintenance. The discussion highlights the importance of understanding cancer testing methods, the reality of remission, and innovative therapies that support the immune system. Additionally, the episode emphasizes the significance of lung health through exercise and the critical role of dental hygiene in overall health. The conversation concludes with exciting developments in rejuvenation procedures that promise significant health benefits.   For the audience ·      Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !    Takeaways   ·      The mitochondria play a crucial role in energy production and immune response. ·      Ozone therapy can rejuvenate mitochondrial function and aid in detoxification. ·      Frequent sexual activity can improve reproductive health for men. ·      Inositol can help women with PCOS improve their chances of pregnancy. ·      Adequate iodine levels can significantly impact a baby's IQ. ·      Regular exercise is beneficial for both pregnancy and overall health. ·      Avoiding heat exposure is important for male fertility. ·      Genetic testing can provide insights into breast cancer risk. ·      Mammograms are not the only screening method for breast cancer. ·      Circulating tumor cell tests can detect cancer earlier than traditional methods.  ·      Circulating tumor cells are crucial for cancer detection. ·      Remission does not mean the absence of cancer. ·      Innovative therapies can enhance immune response against cancer. ·      Exercise is vital for maintaining lung health. ·      Dental hygiene impacts systemic health significantly. ·      Root canals may lead to latent infections affecting health. ·      Regular exercise improves outcomes for cancer patients. ·      Breathing techniques can enhance lung function during exercise. ·      New rejuvenation procedures show promising results for recovery. ·      Understanding oral bacteria is essential for overall health.   Chapters   00:00 Introduction to Age Hacking and Longevity 10:01 Health Recommendations for Pregnancy: Answering a Listener's Q 21:44 Breast Cancer Awareness and Myths 26:09 Understanding Cancer Detection and Testing 28:50 The Reality of Cancer Remission 30:43 Innovative Cancer Therapies and Immune System Support 35:02 Enhancing Lung Health Through Exercise 43:00 The Importance of Dental Hygiene 48:43 Exciting Developments in Rejuvenation Procedures   Articles, News and Supplements mentioned Breast Cancer BREAST CANCER MYTHS https://www.wkrn.com/news/tennessee-news/breast-cancer-awareness-month-common-myths-about-the-disease/   BREAST CANCER GUIDE EVERYONE SHOULD HAVE https://www.telegraph.co.uk/health-fitness/conditions/cancer/breast-cancer/   NEW TECH FOR CANCER SCREENING https://www.cbsnews.com/chicago/news/doctor-talks-new-technology-importance-of-breast-cancer-screenings/   NEW WAY TO KILL CANCER CELLS https://medicalxpress.com/news/2024-10-cancer-cells-longer-people-breast.html   Healthy Lungs BENEFITS OF EXERCISE FOR PATIENTS WITH LUNG CANCER https://medicalxpress.com/news/2024-10-people-lung-cancer-grueling-evidence.html   HABITS PULMONOLOGISTS ARE BEGGING PEOPLE TO ADOPT AND DITCH https://parade.com/health/the-one-habit-to-adopt-asap-if-you-have-severe-asthma-according-to-pulmonologists   Dental Hygiene DENTAL HEALTH SENSING WITH SONIC TOOTHBRUSH https://medicalxpress.com/news/2024-10-exploring-dental-health-sonic-toothbrush.html   DENTAL HYGIENIST TALKS ABOUT HOW TO SPOT PERIODONTAL DISEASE https://www.buzzfeed.com/meganeliscomb/smell-your-used-floss-tiktok   UGLY YET MOST HIGHLY EFFECTIVE TOOTHBRUSH REVIEWERS HAVE EVER USED https://www.huffpost.com/entry/flossing-toothbrush_l_66fefb0de4b089d324aa50b1/amp   Supplements MOLECULAR HYDROGEN – ENERGY https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-30-ct   MOLECULAR HYDROGEN – CHILL https://gladdenlongevityshop.com/products/h2-molecular-hydrogen-product-h2-chill   TOOTH AND GUM ESSENTIALS TOOTH PASTE https://gladdenlongevityshop.com/products/tooth-gum-essentials-toothpaste-4oz-1?_pos=1&_psq=dental&_ss=e&_v=1.0   TOOTH AND GUM TONICS https://gladdenlongevityshop.com/products/tooth-gum-tonic-18-fl-oz-1?_pos=2&_psq=dental&_ss=e&_v=1.0    UPGRADED IODINE https://gladdenlongevityshop.com/products/upgraded-memory-4fl-oz?pr_prod_strat=e5_desc&pr_rec_id=ec1b1eb28&pr_rec_pid=8125057761519&pr_ref_pid=8125058580719&pr_seq=uniform    ZINC https://gladdenlongevityshop.com/products/zinc-glycinate-120-gels-1?_pos=1&_psq=zinc&_ss=e&_v=1.0    Send your Qs for future episodes! Email: podcast@gladdenlongevity.com   Reach out to us at: Website: https://gladdenlongevity.com/  Facebook: https://www.facebook.com/Gladdenlongevity/ Instagram: https://www.instagram.com/gladdenlongevity/?hl=en  LinkedIn: https://www.linkedin.com/company/gladdenlongevity YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw 

The Royal Newfoundland Constabulary is warning of potentially lethal drugs circulating in our community... such as carfentanil with as little as a grain or two capable of killing a person. We hear first from the RNC, and then speak with a harm reduction consultant with the NL Centre on Substance Use program of NL Health Services. (The CBC's Mark Quinn with RNC constable James Cadigan, Krissy Holmes with Jane Henderson)

This week, Jonathan Sackier is joined by Prof. Carlos Caldas, a world-leading expert in breast cancer research and clinician scientist at the University of Cambridge. Together, they explore how genomic-based classifications of breast cancer are transforming treatment strategies and improving patient outcomes.  Timestamps: (00:00) – Introduction  (02:00) – Carlos's favourite cuisine   (03:32) – Carlos's journey into oncology   (08:30) – The redefinition of breast cancer   (14:30) – How this taxonomy influences clinical care   (20:15) - Patient-derived xenografts for breast cancer   (28:00) - Circulating plasma cell-free tumour DNA as a marker of tumour burden   (33:00) – Patient derived tumour cells for drug screening   (35:00) – Vitamin B5 and environmental factors in oncology   (38:44) – Current developments in breast cancer aetiology, diagnosis or treatment    (44:00) – The three wishes for the future of healthcare   (45:00) – Outro

Was man teilweise über Vitamin D hört, klingt fast zu schön, um wahr zu sein. Andererseits deuten hunderte verschiedener Forschungsarbeiten darauf hin, dass Vitamin D zur Vorbeugung einer Reihe von Krankheiten beitragen kann – darunter Osteoporose, Depression, Autoimmun- und Herz-Kreislauf-Erkrankungen. Ärzte empfehlen es. Gesundheits- und Fitnesspodcaster sprechen darüber. Vielleicht geht Dir sogar Deine Lieblingstante damit auf die Nerven. Bei all dem Hype ist die Frage berechtigt: "Solltest Du Vitamin D einnehmen?" Hier sind die Antworten – und die neuesten Fakten über ein faszinierendes Vitamin, das ein wahrer Verwandlungskünstler ist. ____________ *WERBUNG: KoRoDrogerie.de: 5% Ermäßigung auf alles mit dem Code „FMM“ beim Checkout. ____________ Ressourcen zur Folge: Literatur: Ratgeber Nahrungsergänzung – Mark Maslow (kostenlos auf MarathonFitness) Blut: Die Geheimnisse unseres flüssigen Organs* – Ulrich Strunz (Heyne) Vitamin D* – Uwe Gröber, Michael F. Holick (Wissenschaftl. Verlagsgesellschaft) Blutuntersuchung (Selbsttest): Vitamin D Test* von Medivere Präparate: D-Form 2.000 K2+* von FormMed D-Form 2.000 K2+ vegan* von FormMed ____________

Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology Innovation at UCLA, where he is also Chief of Cytopathology and Director of International Telepathology. At the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Rao gave Oncology Times reporter Peter Goodwin details of the molecular methods he had just outlined to the conference.

A wild Beyonce conspiracy theory is taking hold, so we're going to explain it. P Diddy's scandals have had people asking who else might be involved, and a lot of attention has landed on Jay Z and Beyonce. Have a listen for all the juicy details...See omnystudio.com/listener for privacy information.

ReferencesChitnis MM, Yuen JS, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway.Clin Cancer Res 2008,14:6364-6370.Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene.Arch Physiol Biochem 2009, 115:58-71.Davies M, Gupta S, Goldspink G, Winslet M. The insulin-like growth factor system and colorectal cancer: clinical and experimental evidence.Int J Colorectal Dis 2006, 21:201-208.Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.J Natl Cancer Inst 2002, 94:972-980.Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence.Novartis Found Symp 2004, 262:247-260; discussion 260-268.Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging.Science 1997, 278:419-424.Doi T, Shimada H, Makizako H, et al. Association of insulin-like growth factor-1 with mild cognitive impairment and slow gait speed.Neurobiol Aging 2015, 36:942-947.Calvo D, Gunstad J, Miller LA, et al. Higher serum insulin-like growth factor-1 is associated with better cognitive performance in persons with mild cognitive impairment.Psychogeriatrics 2013, 13:170-174.Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors.Endocr Rev 1994,15:80-101.Clemmons DR, Seek MM, Underwood LE. Supplemental essential amino acids augment the somatomedin-C/insulin-like growth factor I response to refeeding after fasting.Metabolism 1985, 34:391-395.Runchey SS, Pollak MN, Valsta LM, et al. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study.Eur J Clin Nutr 2012, 66:1146-1152.Brand-Miller JC, Liu V, Petocz P, Baxter RC. The glycemic index of foods influences postprandial insulin-like growth factor-binding protein responses in lean young subjects.Am J Clin Nutr 2005, 82:350-354.Biddinger SB, Ludwig DS. The insulin-like growth factor axis: a potential link between glycemic index and cancer.Am J Clin Nutr 2005, 82:277-278.Burgers AM, Biermasz NR, Schoones JW, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality.J Clin Endocrinol Metab 2011, 96:2912-2920.Ranke MB, Osterziel KJ, Schweizer R, et al. Reference levels of insulin-like growth factor I in the serum of healthy adults: comparison of four immunoassays.Clin Chem Lab Med 2003, 41:1329-1334.Bidlingmaier M, Friedrich N, Emeny RT, et al. Reference intervals for insulin-like growth factor-1 (igf-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations.J Clin Endocrinol Metab 2014, 99:1712-1721.Brabant G, von zur Muhlen A, Wuster C, et al. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study.Horm Res 2003, 60:53-60.Crowe FL, Key TJ, Allen NE, et al. The association between diet and serum concentrations of IGF-I, IGFBP-1, IGFBP-2, and IGFBP-3 in the European Prospective Investigation into Cancer and Nutrition.Cancer Epidemiol Biomarkers Prev 2009,18:1333-1340.Fontana L, Klein S, Holloszy JO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk.Am J Clin Nutr 2006, 84:1456-1462.Fontana L, Weiss EP, Villareal DT, et al. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans.Aging Cell 2008, 7:681-687.Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations.J Clin Endocrinol Metab 2009, 94:1732-1739.Carlzon D, Svensson J, Petzold M, et al. Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men.J Clin Endocrinol Metab 2014, 99:E2308-2316.Svensson J, Carlzon D, Petzold M, et al. Both low and high serum IGF-I levels associate with cancer mortality in older men.J Clin Endocrinol Metab 2012, 97:4623-4630. .van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The Association of Serum Insulin-Like Growth Factor-I with Mortality, Cardiovascular Disease, and Cancer in the Elderly: A Population-Based Study.J Clin Endocrinol Metab 2010.Arai Y, Takayama M, Gondo Y, et al. Adipose endocrine function, insulin-like growth factor-1 axis, and exceptional survival beyond 100 years of age.J Gerontol A Biol Sci Med Sci 2008, 63:1209-1218.Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke.J Clin Endocrinol Metab 2005, 90:5937-5941.Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.Lancet 1998, 351:1393-1396.Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.Science 1998, 279:563-566.

Remember when I was diagnosed with cancer? remember that thing growing on our kid's neck? Remember when our kid had a seizure? What a year!! Oh and David's too helpful! Stop helping, David!!

Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial efficiency and patient experience. Unlike traditional tissue biopsies, which sample a single tumor site, ctDNA offers a real-time, comprehensive view of the genetic mutations present in the tumor throughout the body. By offering faster, more detailed insights than traditional imaging, ctDNA can identify tumor mutations earlier and help clinicians adjust treatments sooner.In this episode of the Syneos Health Podcast, Chief Scientific Officer Nick Kenny is joined by oncology experts Dr. Patrick Kelly and Dr. Wael Harb to discuss how circulating tumor DNA (ctDNA) is transforming cancer treatment and clinical trial design, and its potential to drive more patient-centric, adaptive clinical trials. Find all of our oncology-related insights on our Insights Hub here.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

WATCH ON YOUTUBE: https://youtu.be/ZNzsha1XJwE.Join Shayn & Orin as we discuss what conspiracy theories are circulating the 2024 election. Thanks for checking out the 14th episode of "Bizarre Inquiries". Don't forget to submit your own bizarre inquiry, clip, or article for us to discuss on the show!Do us a favor and like, follow, share, & leave a review! We appreciate it!.Article: https://www.thedailybeast.com/the-most-outrageous-conspiracy-theories-of-the-2024-election-yet.Do you want join the discussion on this weeks bizarre inquiry?Join the discord and post your thoughts in the "Bizarre Inquiries" channelhttps://discord.com/invite/pPNa84ZEjp.*4 NEW MERCH DESIGNS AVAILABLE NOW!*Use code "CRYPTID10" for 10% off the OMM Merch Store!https://open-minds-media.creator-spring.com/.Social Media/Email/Donate/Merch/Patreonhttp://linktr.ee/open_minds_media..REPORT AN ENCOUNTERommencounterreports@outlook.com..Affiliate Link:Chattergeist by Dimension Deviceshttps://dimensiondevices.co.uk/shop.php?affiliate=OpenMindsMediahttps://www.instagram.com/dimension.devices/..Please Check Out:.Bizarre EncountersSocial Media/Email/Donate/Merch/Patreonhttp://linktr.ee/bizarreencounters..Inquiries of our Reality (Shayn)Social Media/Email/Donate/Merch/Patreonhttp://linktr.ee/inquiriesofourrealitypodcast..The Framework: UFO Research Center (Orin)https://www.instagram.com/theframeworkufo/..Open Minds Media (OMM)https://linktr.ee/open_minds_media..Phantoms & Monsters Fortean Research Teamhttps://www.phantomsandmonsters.com/p/phantoms-monsters-fortean-research.html..SPONSORS:.IKNOWSQUATCHSpreading the gospel of Squatch with knowledge & fresh merchhttps://www.etsy.com/shop/iknowsquatch?ref=shop_sugghttps://www.instagram.com/iknowsquatch/..CryptoteeologySpecializing in wearable cryptids and monsters and the stories behind them. Discover a relatable monster for any casual occasion.https://www.cryptoteeology.com/https://www.instagram.com/cryptoteeology/https://www.facebook.com/Cryptoteeology..The Snarly Yow Beard & Body ProductsSnarly Products are made exclusively for the Snarly Yow by crafters and local small businesses by hand.https://www.snarlyyow.com/https://www.instagram.com/thesnarlyyowhttps://www.facebook.com/TheSnarlyYow/..Phantoms & Monsters Fortean Research Teamhttps://www.phantomsandmonsters.com/p/phantoms-monsters-fortean-research.html..Intro & Outro By:Socio-Beathttps://distrokid.com/hyperfollow/sociobeat/conundrumhttps://socio-beat.bandcamp.com/..Support this podcast at — https://redcircle.com/bizarre-encounters/donations

Welcome back friends, to another episode of Empower Project Radio. I am so jazzed about this conversation today. We are talking all about MONEY. We're talking about MINDSET. We're talking about high earning and the high earning money blocks that come along with it. Join me, KC Volard, while I pick the brain of global money coach, Kristen Wonch. Check out Kristen's free program offering here. Want to see Kristen live in-person? She's a panelist alongside other multiple 6-figure earners at As She Rises LIVE in Montreal September 21-22, 2024. Do you have your ticket yet? Get yours HERE!The As She Rises Live Event is an Embodiment & Business Conference for Spiritual Entrepreneurs, Mystics, Healers and Visionaries from around the world.An epic, ground shattering and transformational event. Take a screenshot and tag me on Instagram (@iamkcvolard)!Let me know what you're loving!Let's continue the conversation over inside our FREE telegram community - The 7-Figure Coven!

Join Mark and Chandru in this episode as they unravel the concept of circulating supply within the cryptocurrency ecosystem. In this episode, circulating supply is discussed both from a crypto and legal perspective. They further explore the terms vesting, vested, allocated, unallocated, locked and unlocked.

Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

Dr. Neeraj Agarwal and Dr. Rana McKay discuss promising studies in GU cancers featured at the 2024 ASCO Annual Meeting that highlighted improved outcomes in urothelial carcinoma, improved survival in renal cell carcinoma, and the role of ctDNA as a potential biomarker for predicting outcomes.   TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah's Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News.  I am delighted to welcome Dr. Rana McKay, a GU medical oncologist and associate professor at the University of California San Diego. Today, we'll be discussing some key GU abstracts featured at the 2024 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Rana, we're thrilled to have you on the podcast today to share your insights on key advances in GU oncology from ASCO24. Dr. Rana McKay: Thank you so much, Neeraj; it's a pleasure to be here. Dr. Neeraj Agarwal: So, Rana, let's start with some bladder cancer abstracts. Could you tell us about Abstract 4503, titled “Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer”? Dr. Rana McKay: Of course, I would be delighted to. First, I would like to remind our listeners that enfortumab vedotin (EV) was approved as a monotherapy for the treatment of locally advanced or metastatic urothelial cancer based on the results of EV-201 and EV-301 trials. In these pivotal studies, EV was initiated at a dose of 1.25 mg/kg, and dose modifications, such as reductions and interruptions, were used to manage adverse events. In the abstract presented at ASCO 2024, Dr. Daniel Petrylak and colleagues conducted a post-hoc exploratory analysis to evaluate the association between EV plasma exposure and outcomes. They used multiple pharmacokinetic samples collected during the first two cycles and pre-dose samples from 3 EV monotherapy studies, namely EV-101, EV-201, and EV-301, that were conducted in patients with previously treated locally advanced or metastatic urothelial carcinoma. Dose reductions to 1 mg/kg were required in 42.1% and 35.1% of patients in the EV-201 and EV-301 trials, respectively, and reductions to 0.75 mg/kg were required in 13.6% and 11.1% in the EV-201 and EV-301 trials, respectively. Higher EV exposure during the first two cycles was associated with a higher objective response rate. The ORR was 21.4% for the dose of 0.75 mg/kg, while it was 18.5% for the dose of 1.0 mg/kg. Interestingly, increasing the dosage to 1.25 mg/kg improved the ORR, which ranged from 40 to 51.1% across various studies. In the EV-301 trial, when comparing the efficacy of EV to chemotherapy, EV improved PFS and OS across all dose quartiles, and there was no evidence that recommended dose modifications impacted long-term efficacy outcomes. Dr. Neeraj Agarwal: Thank you, Rana, for this great summary. I would like to add that the meticulously conducted pharmacokinetic studies demonstrated that serum levels of EV correlated with responses. Importantly, patients who had to decrease the dose did not experience compromised outcomes as EV improved PFS and OS outcomes vs chemotherapy in across all exposure quartiles in the EV-301 trial where EV was compared with chemotherapy. These findings highlight the need to start at the recommended dose of 1.25 mg/kg and reduce it, if necessary, however, clinicians should not start at a lower dose.  Dr. Rana McKay: I totally agree with you, Neeraj. Now, moving on to a different setting in bladder cancer, what can you tell us about LBA4517, titled “Perioperative sacituzumab govitecan alone or in combination with pembrolizumab for patients with muscle-invasive urothelial bladder cancer: SURE-01/02 interim results”? Dr. Neeraj Agarwal: Of course! So, SURE was a multicohort, open-label, phase 2 study in patients with muscle-invasive bladder cancer assessing sacituzumab govitecan as a neoadjuvant therapy either alone in SURE-01 or as a combination with pembrolizumab followed by adjuvant pembro in SURE-02 in a flexible design allowing a bladder-sparing approach. In the abstract presented at ASCO 2024, Dr. Antonio Cigliola and colleagues report interim results of the SURE-01 study. Patients with cT2-4N0M0 urothelial carcinoma who were ineligible for or refused cisplatin-based neoadjuvant chemotherapy were planned to receive 4 cycles of neoadjuvant sacituzumab govitecan at a dose of 10 mg/kg followed by radical cystectomy.  An extensive assessment was performed at baseline and after the 4 cycles for response assessment. Patients with clinical complete response defined with negative MRI, cystoscopy and ctDNA assays refusing radical cystectomy were offered redo transurethral resection of the bladder tumor or repeat TURBT followed by observation in the absence of viable high-grade tumor in the bladder. The primary endpoint was pathological complete response rate, while secondary endpoints included pathological downstaging rate and safety. After the first 8 patients were enrolled, the protocol was amended due to the occurrence of grade 3 and 4 neutropenia and diarrhea in 75% and 50% of patients, respectively, and 2 deaths – one of which was deemed to be treatment-related due to sepsis. Key protocol changes included the reduction of the dose of sacituzumab govitecan to 7.5 mg/kg, the introduction of G-CSF as primary prophylaxis, and the exclusion of patients at high risk of febrile neutropenia per ASCO guidelines.  Among 21 patients who received at least one cycle of sacituzumab govitecan and included in the intention-to-treat population, 47.6% had a complete pathological response, and 52.4% had pathological downstaging. 11 patients underwent radical cystectomy, while 7 received repeat-TURBT due to complete clinical response or patient preference. Regarding the safety profile, grade 3 or more adverse events occurred in 42.5% of patients. Treatment-related adverse events leading to dose interruptions or discontinuations were more common before the protocol amendment. It is noteworthy that 3 patients died after treatment discontinuation, with one deemed treatment-related, as previously mentioned. Dr. Rana McKay: Thank you, Neeraj, for a great summary. The pathological complete responses observed show promising activity for sacituzumab govitecan as a neo-adjuvant therapy and a window for bladder-sparing approaches, which is definitely exciting news for our patients! However, although the 3 deaths encountered in a neo-adjuvant setting could be concerning, the improvement of the safety profile after protocol amendments is reassuring and supports the continuation of the study. Dr. Neeraj Agarwal: Before wrapping up the bladder cancer section, would you like to share your insights with our listeners on Abstract 4518, titled “Quantitative circulating tumor DNA (ctDNA) assessment in patients with advanced urothelial carcinoma treated with pembrolizumab or platinum-based chemotherapy from the phase 3 KEYNOTE-361 trial”?  Dr. Rana McKay: Sure. So, the KEYNOTE-361 trial was a randomized phase 3 study with 3 arms that included pembrolizumab plus chemotherapy, pembrolizumab monotherapy, or chemotherapy alone in patients with previously untreated advanced urothelial carcinoma. The results showed that neither the combination of pembrolizumab plus chemotherapy nor pembrolizumab monotherapy improved survival outcomes compared to the chemotherapy arm. So, in this exploratory analysis presented at ASCO24, Dr. Tom Powles and colleagues sought to assess the role of ctDNA as a potential biomarker between the pembrolizumab monotherapy arm and the chemotherapy arm. Tumor tissue mutations were evaluated using whole exome sequencing, and plasma ctDNA was assessed with the Guardant 360 assay. Changes in ctDNA from pre-treatment cycle 1 to on-treatment cycle 2, so 3 weeks post-baseline assessment, were quantified by the maximum variant allele frequency of tumor tissue-specific mutations.  Results showed that lower baseline ctDNA levels were associated with improved clinical outcomes of response in the pembrolizumab arm but not in the chemotherapy arm. This improvement in the pembrolizumab arm was also robust to adjustment for tumor mutational burden and PD-L1. Additionally, chemotherapy led to a ctDNA clearance rate of 41% compared to 11% in the pembrolizumab arm. Patients who had a large ctDNA reduction with pembrolizumab had significantly improved outcomes compared to those achieving a large reduction with chemotherapy with a hazard ratio of 0.25. However, this did not replicate in patients who did not achieve a large reduction, as these patients had similar outcomes across both arms. Let's switch gears to kidney cancer and start with Abstract 4508, reporting the final OS analysis from the JAVELIN Renal-101 trial. Neeraj, what would you like to tell us about this abstract? Dr. Neeraj Agarwal:  Well, as a quick reminder, the JAVELIN Renal-101 was a randomized phase 3 trial where patients with previously untreated advanced or metastatic clear cell renal cell carcinoma were randomized to receive either the combination of avelumab plus axitinib or sunitinib. In previous analyses, the combination of avelumab and axitinib significantly improved PFS compared to sunitinib and was subsequently approved by the FDA for the first-line treatment of patients with advanced RCC in 2019. This superiority in PFS was maintained across the different analyses; however, OS data remained immature. In the abstract presented at ASCO24 by Dr. Robert Motzer from Memorial Sloan Kettering Cancer Center and colleagues, the authors reported OS results at a median follow-up of around 73 months and a minimum of 68 months for all patients, which is the longest follow-up for any ICI-TKI combination in RCC. The final analysis in the overall population favored the combination of avelumab plus axitinib with a median OS of 44.8 months compared to 38.9 months with sunitinib, however, this did not reach statistical significance with a hazard ratio of 0.88. The PFS results and safety profile were consistent with previous analyses.  Dr. Rana McKay: Thank you, Neeraj, for such a nice overview of this abstract. These new data could make this regimen less optimal than other ICI-TKI combinations in the first-line mRCC setting.   Dr. Neeraj Agarwal: I concur, Rana. Moving on to perhaps one of the most exciting GU abstracts featured, Abstract 4506, titled “Circulating kidney injury molecule-1 biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection.” Rana, what are your thoughts on this abstract? Dr. Rana McKay: Well, first, I would like to take a step back and remind our audience that in the IMmotion010 trial, patients with resected intermediate to high-risk RCC with clear cell and/or sarcomatoid component were randomized in a 1:1 ratio to receive either atezolizumab or placebo. Investigator-assessed disease-free survival, which was the primary endpoint, favored the atezolizumab arm but did not reach statistical significance. In the abstract featured at ASCO24, Dr. Laurence Albiges and colleagues build on data previously reported in the ASSURE and CheckMate 914 trials and report provocative findings regarding a molecule known as kidney injury molecule 1 or KIM-1, which is a type 1 membrane glycoprotein that has been identified as a minimally invasive potential peripheral blood circulating biomarker. The KIM-1 level of 86 pg/ml was identified as the optimized threshold for defining post-nephrectomy KIM-1 high vs KIM-1 low subgroups in the IMmotion010 trial. KIM-1 levels were measured at baseline or pre-treatment, at cycle 4 day 1, and at disease recurrence or discontinuation without disease recurrence. Baseline characteristics were balanced between the KIM-1 high and KIM-1 low groups, except perhaps for a slightly higher pathological stage in the KIM-1 high subgroup.  I would like to highlight 3 key takeaways from this abstract. First, KIM-1 high level was associated with significantly worse DFS with a hazard ratio of 1.75. Second, patients in the KIM-1 high subgroup receiving atezolizumab had a 28% reduction in the risk of recurrence or death compared to those receiving placebo, while those in the KIM-1 low subgroup had comparable outcomes across both treatment arms. Third, patients in the KIM-1 high subgroup receiving atezolizumab were significantly less likely to experience an on-treatment increase in KIM-1 levels, which was associated with worse DFS in both high and low KIM-1 subgroups, regardless of treatment arm. Thus, these findings support the use of KIM-1 as both a predictive and prognostic biomarker in patients with RCC. Dr. Neeraj Agarwal: Yes, Rana, this is amazing data! I would like to add that these results warrant larger and, ideally, prospective studies to validate the utility of KIM-1 as a noninvasive biomarker for identifying minimal residual disease after nephrectomy and for predicting outcomes to immune checkpoint inhibitors. Dr. Rana McKay: Also, in the field of biomarkers, 2 abstracts interrogating different biomarkers in a different setting, so in patients with advanced or metastatic RCC were presented. Neeraj, could you tell us more about these abstracts? Dr. Neeraj Agarwal: Of course! I think you are referring to Abstracts 4504 and 4505. In abstract 4504, Dr. Toni Choueiri and colleagues sought to assess the clinical implications of different biomarkers in the CLEAR trial, which was a randomized phase 3 trial that led to the approval of the combination of pembrolizumab plus lenvatinib in the first-line mRCC setting. On the other hand, in abstract 4505, Dr. Brian Rini presented biomarker results in KEYNOTE-426, which was also a randomized phase 3 trial based on which the combination of pembrolizumab plus axitinib was approved in patients with mRCC. The authors in both trials sought to investigate the role of biomarkers in predicting treatment outcomes from 3 different angles. Starting with PD-L1 expression, the superiority of the combination arms over sunitinib was not impacted by PD-L1 status in both trials. Moving on to RCC driver gene mutations on whole exome sequencing, such as VHL, SETD2, PBRM1, and BAP1, ICI combination therapies improved outcomes regardless of mutation gene status, and this improvement was statistically significant with PBRM1 mutations in KEYNOTE-426 compared to wild-type PBRM1, but this did not replicate in the CLEAR trial. Finally, using transcriptomic signatures derived from RCC trials, especially the IMmotion 151 and JAVELIN Renal 101 trials, where 7 clusters or molecular subtypes were identified, the combination arms outperformed sunitinib in all clusters in both trials and the magnitude of this benefit differed across clusters.  Dr. Rana McKay: Thank you for this very interesting summary and comparison of the results of these 2 abstracts. These findings support the use of ICI-based combinations in all patients with mRCC as a first-line option. Although these abstracts could not identify specific biomarkers that could guide us clinicians in treatment selection, they provide very interesting biological insights on these molecular biomarkers that are, however, not yet clinically actionable. Dr. Neeraj Agarwal: Very interesting point, Rana. Moving on to prostate cancer, let's start with abstract LBA5000 titled, “Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).” Rana, what is your takeaway on this abstract? Dr. Rana McKay: As a reminder to our audience, the CHAARTED2 trial was a randomized open-label phase 2 study that compared the combination of cabazitaxel and abiraterone to abiraterone alone in patients with mCRPC previously treated with ADT plus docetaxel in the hormone-sensitive setting. The primary endpoint was progression-free survival. After a median follow-up of 47.3 months, Dr. Christos Kyriakopoulos and colleagues reported in LBA5000 that patients receiving the combination of cabazitaxel plus abiraterone had a 27% reduction in the risk of progression or death. However, there was no significant difference in overall survival between the two arms, with a median OS of 25 months in the cabazitaxel+abiraterone arm and 26.9 months in the abiraterone arm, although the study was underpowered for this endpoint. Regarding the toxicity profile, the combination of cabazitaxel and abiraterone was overall well tolerated with more cytopenias, as expected.  Dr. Neeraj Agarwal: Very nice summary of this abstract, Rana. I would like to add that the treatment landscape of patients with mHSPC has evolved since the design of the study and now includes combination therapies of ADT + ARPI with or without docetaxel, and ADT + docetaxel is no longer a standard of care, which limits the applicability of these results in clinical practice today.  Dr. Rana McKay: Excellent point, Neeraj. Let's discuss Abstract 5001, titled “CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer”. Dr. Neeraj Agarwal: Sure! In the abstract featured at ASCO24, Dr. Matthew Smith and colleagues report the primary results of the CYCLONE 2 trial, which was a randomized phase 2/3 study that investigated the combination of abemaciclib plus abiraterone versus abiraterone monotherapy in patients with mCRPC. Stratification factors included radiographic progression at study entry, presence of measurable disease, and prior docetaxel for mHSPC. Part 1 of the study established the recommended phase 2 dose of abemaciclib at 200 mg twice daily. In part 2, patients were randomized to placebo or abemaciclib, and an adaptive interim analysis using prespecified criteria was performed and recommended the expansion of the study to part 3. The primary endpoint was investigator-assessed radiographic progression-free survival by RECIST 1.1 and PCWG3 criteria in the intention-to-treat population. At the time of the primary analysis, adding abemaciclib to abiraterone did not improve rPFS, with a hazard ratio of 0.83. The median rPFS was 22 months for the combination arm and 20.3 months for the abiraterone arm. The combination was well tolerated, and the safety profile was consistent with the known adverse events. Dr. Rana McKay: So, the addition of abemaciclib to abiraterone did not improve outcomes in patients with mCRPC. These findings suggest that no further investigation is warranted for abemaciclib or CDK4/6 inhibitors in biomarker-unselected patients with prostate cancer.  Dr. Neeraj Agarwal: Rana, what's your take-home message on Abstract 5006, titled “Health-related quality of life results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer”? Dr. Rana McKay: So, as a reminder to our audience, the PRESTO trial was a randomized phase 3 study that assessed the effects of intensified androgen receptor blockade in patients with biochemically recurrent prostate cancer following local therapies. Patients with a PSA doubling time of less than 9 months and no evidence of metastatic disease were randomized to receive either 52 weeks of ADT alone, ADT plus apalutamide, or ADT plus apalutamide plus abiraterone. In their paper published earlier this year in the Journal of Clinical Oncology, the authors showed that patients receiving ADT plus apalutamide with or without abiraterone had significantly longer PSA-progression-free survival than those receiving ADT alone. In the oral presentation featured at ASCO24, Dr. Ronald Chen and colleagues report health-related quality of life outcomes that were assessed using various questionnaires or scales at baseline, at cycle 7, which is around 6 months on treatment, and at the end of treatment. Results showed that this intensified approach with apalutamide did not significantly increase severe adverse events, did not lengthen the time to testosterone recovery, and did not meaningfully increase common treatment-related symptoms such as hormonal symptoms, sexual dysfunction, hot flash interference, and fatigue. Importantly, additional intensification with abiraterone did not further improve PSA-PFS but did increase the rate of serious adverse events, lengthened the time to testosterone recovery, and increased hot flash interference.  Dr. Neeraj Agarwal: So, in conclusion, the PRESTO trial supports using intensified androgen blockade with apalutamide to improve PSA-PFS in patients with high-risk biochemically recurrent prostate cancer without compromising health-related quality of life. However, adding abiraterone did not offer additional benefits and increased side effects.  Dr. Rana McKay: Let's move on to LBA5002 titled, “A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.” Would you like to share your insights on this abstract with our listeners? Dr. Neeraj Agarwal: Absolutely. MAST was a randomized, double-blinded, placebo-controlled trial that investigated the impact of metformin on the progression of low-risk localized prostate cancer in patients choosing to undergo active surveillance. Eligible patients had biopsy-proven, low-risk, localized prostate cancer diagnosed within the past 6 months, characterized by a Gleason score of less than 6 observed in less than one-third of the total cores, less than 50% positivity in any one core, a PSA level of less than 10 ng/ml, and a clinical-stage between T1c and T2a. Patients were randomized in a 1:1 ratio to receive either metformin 850 mg twice daily or placebo for three years. All patients underwent repeat prostate biopsy at 18 and 36 months. The primary endpoint was time to progression, defined as the earliest occurrence of primary prostate cancer therapy, such as prostatectomy, radiation, hormonal therapy, or pathological progression on subsequent biopsies, which was defined as more than 1/3 of total cores involved, at least 50% of any one core involved, or Gleason pattern 4 or higher. The study included 407 patients, with 204 receiving metformin and 203 receiving a placebo. Results presented by Dr. Anthony Joshua showed no statistically significant difference in progression-free survival, including therapeutic and pathologic progression, with an unadjusted hazard ratio of 1.08.  Interestingly, there was a signal that patients with a BMI more than 30 had a detriment to taking metformin with a higher risk of progression compared to those receiving placebo with an unadjusted HR of 2.39 and a p-value of 0.01. Dr. Rana McKay: I would like to add that this study showed that metformin use does not prevent the progression of low-risk localized prostate cancer on active surveillance and could represent a potential detriment for patients with high BMI at study entry. Dr. Neeraj Agarwal: Yes, Rana, I concur. Any final remarks before we conclude today's podcast? Dr. Rana McKay:  Thank you, Neeraj; it's been wonderful being here with you today and you having me on the podcast to highlight these important advances and the amazing work that many investigators are conducting and the patients who were involved in the context of these trials. It's really excellent to see these updated results.   Dr. Neeraj Agarwal: Before we wrap up this podcast, I would like to say that we have reviewed a selection of abstracts addressing prostate, bladder, and kidney cancer, which are significantly impacting our medical practices now and in the near future. Rana, thank you for sharing your insights today. These updates are undoubtedly exciting for the entire GU oncology community, and we greatly appreciate your valuable contribution to the discussion. Many thanks. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Find out more about today's speakers:    Dr. Neeraj Agarwal   @neerajaiims   Dr. Rana McKay  @DrRanaMcKay     Follow ASCO on social media:      @ASCO on Twitter      ASCO on Facebook      ASCO on LinkedIn         Disclosures:        Dr. Neeraj Agarwal:         Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences     Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas      Dr. Rana McKay:   Consulting or Advisory Role: Janssen, Novartis, Tempus, Exelxis, Pfizer, Bristol-Myers Squibb, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion, Calithera, AstraZeneca, Myovant, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Pfizer, Bayer, Tempus

In this JCO Precision Oncology Article Insights episode, Fergus Keane provides a summary on "Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers" by Belmont, et al published on May 9th, 2024. TRANSCRIPT  Fergus Keane: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Fergus Keane, an ASCO editorial fellow. Today I will be providing a summary of the article entitled, "Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers" by Dr. Erika Belmont and colleagues.  While appendiceal cancers represent an uncommon diagnosis, the incidence has been rising, with now over 3000 new cases per year diagnosed in the United States. The management of appendiceal cancers includes surgical resection for localized tumors and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, also known as HIPEC, for select patients with peritoneal metastasis. For patients with higher grade appendiceal cancers, systemic therapy is often included in the treatment paradigm. However, little data pertaining to the optimal treatment regimens exists.  Despite best practice, disease recurrence within three years of surgery will be observed in about 70% of cases of appendiceal cancers. The current conventional methods for surveillance for both detection of recurrence as well as for assessment of response to systemic therapy are using cross sectional imaging and serum tumor markers. These methods are limited and there is a recognition that more accurate biomarkers are required. Circulating tumor DNA, also known as liquid biopsies, refer to shed tumor DNA identified in the plasma. Several ctDNA assays exist, including tumor agnostic assays and tumor informed assays, the latter of which assess presence of personalized tumor derived mutations. The utility of circulating tumor DNA has been studied across several different cancer types and in several different disease settings, for instance in lung cancer and colorectal cancer. However, it has not been well demonstrated to date in appendiceal cancers.  This study aimed to investigate the role of the Signatera ctDNA assay in patients with appendiceal cancer. Specifically, the authors aimed to evaluate factors associated with circulating tumor DNA detection and the association between ctDNA and recurrence free survival after surgery. Their hypothesis was twofold, firstly, that circulating tumor DNA detection would be reduced in patients who received recent systemic therapy, and secondly, that circulating tumor DNA detection after cytoreductive surgery and HIPEC would be associated with a shorter recurrence free survival across all appendiceal cancer grades. The study design was a retrospective review of patients with appendiceal cancers treated at MD Anderson Cancer Center in Texas and the University of Chicago who underwent circulating tumor DNA testing between January 2019 and December 2022. Clinical, pathologic and treatment related information was collected for all patients. Regarding patient treatment, all patients received treatment as per the consensus recommendations at both cancer centers. Diagnostic evaluation was with CT or MRI imaging and serum tumor markers. Diagnostic laparoscopy was performed to evaluate for the presence of peritoneal metastases. The patient treatment plans were determined via MDT tumor board discussions and cytoreductive surgery, and HIPEC was offered with curative intent to eligible patients.  Systemic therapy with 5-FU based doublet or triplet therapy with or without VEGF inhibitors was offered to patients with grade two or three tumors and with a good performance status. HIPEC protocols involved the use of mitomycin C. Postoperative surveillance involved cross sectional imaging and tumor marker evaluation every three months for two years and thereafter every six months if the patients remain disease-free. Circulating tumor DNA testing was offered at the discretion of the treating physician, typically every three months after surgery. The Signatera assay is a personalized, multiplexed, PCR based next generation sequencing platform. Three major analyses were performed. Number one, the frequency of any time ctDNA detection was evaluated in patients with ctDNA assays drawn at the time of radiographic or laparoscopically identifiable disease. Number two, the correlation between preoperative ctDNA levels and intraoperative peritoneal cancer index was evaluated in patients with peritoneal metastases. The third analysis involves the association between circulating tumor DNA presence drawn within one year of optimal resection.  A total of 402 plasma samples were obtained from 94 patients from the two centers. Most patients had grade 2 or 3 appendiceal cancers and 85% underwent surgery. Most patients had peritoneal metastases. 50 patients had circulating tumor DNA assessment in the presence of stage 4 disease, included in this, 13 patients were tested preoperatively, 26 patients who developed recurrence after surgery were included, and 11 patients who did not undergo surgery. In total, circulating tumor DNA was detected in 66% of these patients. The detection frequency was 57.1% in patients with grade 1, 62.5% in patients with grade 2, and 70.4% in patients with grade 3 disease, but this variability did not meet statistical significance. Lower circulating tumor DNA detection was observed in patients who received systemic therapy within six weeks before ctDNA assessment at 43.8% versus 76.5%, and multivariate analysis confirmed this association, demonstrating that recent systemic therapy was associated with an odds ratio of 0.22 versus less recent systemic therapy.  17 patients underwent circulating tumor DNA testing before cytoreductive surgery, and HIPEC and circulating tumor DNA was detected in 23.5% of these cases. No correlation was observed between ctDNA detection and intraoperative PCI index in these patients. Among the 50 patients with ctDNA testing within one year of optimal resection, survival estimates were generated for 36 patients who underwent cytoreductive surgery and HIPEC for grade 2 and 3 appendiceal cancers. The median follow up was 19.6 months. Circulating tumor DNA detection after cytoreductive surgery was associated with a shorter median recurrence free survival of 11.3 months versus not detected in those without ctDNA detection. On multivariate analysis, this was confirmed. The median time interval between surgery and ctDNA detection was 31 weeks. In this cohort of 36 patients, 44.4% or 16 patients developed disease recurrence. During the surveillance period, ctDNA was elevated in 93.8% of these patients, demonstrating a higher sensitivity than CEA, CA 19-9 or CA 125 tumor markers. Only one patient with disease recurrence had negative ctDNA at that time. Among these 16 patients with disease recurrence, one patient with a positive ctDNA test had their first sample drawn after diagnosis of disease recurrence, and one patient who had extensive adjuvant systemic therapy developed ctDNA negative recurrence. In the remaining 14 patients, circulating tumor DNA detection preceded the diagnosis of recurrence on imaging by a median of 11 weeks.   In summary, this study is a large, retrospective report of tumor-informed circulating tumor DNA testing in patients with appendiceal cancers. This study is one of the first to elucidate the factors associated with circulating tumor DNA detection in this disease and a potential role for circulating tumor DNA as an adjunct tool in the surveillance of patients with this malignancy.  Again, I'm Fergus Keane, a JCO Precision Oncology Editorial Fellow. Thank you for listening to the JCO Precision Oncology Article Insight. Please tune in for the next topic. Don't forget to give us a rating or review, and be sure to subscribe so that you never miss an episode. You can find all ASCO shows at www.asco.org/podcasts.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

(Bloomberg) -- The World Health Organization warned that fake batches of Novo Nordisk A/S's hit diabetes drug Ozempic have been circulating amid soaring demand for the medicine, which some patients use to lose weight.  Three falsified batches were identified in Brazil and the UK in October of last year and in the US in December, the WHO said on Thursday. Though the global public health body has been monitoring growing numbers of reports of fake semaglutide, as Ozempic is known generically, since 2022, this is the first time it has issued an official warning notice.

Chad also discusses peaceful protesters vandalizing landmarks.

Chad also discusses peaceful protesters vandalizing landmarks.

Weightlifting Talk

In this podcast, UROONCO RCC chief editor Dr. Maria Carmen Mir (ES) talks to Prof. Laurence Albiges (FR) on the abstract she recently presented at ASCO2024 - “Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomised phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection”.  Prof. Albiges details the two parts of the circulating biomarker analysis scheme, part one - biomarker identification/screening; and part two - assessing the association of circulating kidney injury molecule-1 with disease free survival outcomes.   The study results are discussed in detail and Prof. Albiges talks about what research is needed in the future to confirm the utility of circulating serum kidney injury molecule-1 in adjuvant RCC as a non-invasive biomarker. 

Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

In this JCO Precision Oncology Article Insights episode, Mitchell Elliot provides a summary on "Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer" by Shaw, et al published on May 1st, 2024. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Mitchell Elliott: Hello and welcome to the JCO Precision Oncology Article Insights. I'm your host, Mitchell Elliott, an ASCO Journal editorial fellow. Today I will be providing a summary of the article titled, “Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long Term Follow up in Patients with Breast Cancer,” by Dr. Jacqueline Shaw and colleagues.  Circulating tumor DNA is shed readily into the peripheral blood by tumors. ctDNA makes up a small fraction of the total cell free DNA in the peripheral blood and can be detected using highly sensitive assays. ctDNA assays can be tumor-informed where blood samples are tested for the presence of tumor specific mutations, which are selected by sequencing the primary tumor, so the panels are patient specific. Tumor agnostic assays also exist which are typically looking for the presence of cancer driver mutations or cancer derived methylation signals, which are not patient specific but rather cancer specific. Several retrospective analyses of clinical trials and cohorts have demonstrated that the identification of ctDNA in patients in follow-up can predict relapse in breast cancer, lung cancer, and colon cancer. Personalized tumor informed assays have demonstrated high technical specificity, but to date there is no gold standard assay identified and no direct comparison between all of the available assays. While the literature to date has demonstrated that identification of ctDNA prior to clinical relapse is possible, no study has demonstrated that it improves patient outcomes.  In this specific study, the authors evaluated the Signatera assay, a tumor informed assay based on whole exome sequencing, enabling the design of personalized panels for up to 16 tumor specific variants detected via multiplex PCR next generation sequencing. This was evaluated in the exploratory breast lead interval study or EBLIS, which is a study based out of the United Kingdom. EBLIS is a multicenter prospective cohort study funded by Cancer Research UK and the National Institute of Health Research that opened for recruitment in 2012. This was a retrospective analysis so no results were directly shared with patients or physicians. Patients were eligible if they were 18 years or older, had histologically confirmed breast cancer and must have completed all surgery and chemotherapy within three years of entry into the study. They had to have an adjuvant online risk relapse at greater than 65% or mortality of greater than 50% at 10 years, which defines a very high risk subgroup for study enrollment.  The results of this study and the baseline patient characteristics reflected the predefined clinical risk. The majority received neoadjuvant or adjuvant chemotherapy. Most patients were diagnosed with invasive ductal carcinoma and were staged 2b to 3c. There were 156 patients identified from this cohort after 28 had insufficient DNA and 3 had unsuccessful whole exome sequencing, which are required for the assay generation. Of the 156 patients, there were 1136 plasma time points evaluated. Of the 1136 plasma time points, ctDNA was identified in 46, which represents approximately 4% of the total time points in this high risk cohort. 34 patients have experienced disease relapse, including 22 with hormone receptor positive HER2 negative disease, three with hormone receptor positive HER2 positive disease, seven with triple negative breast cancer, and two with hormone receptor negative HER2 positive disease. ctDNA was detected in 30 of the 34 patients who had a subsequent relapse with a patient specific sensitivity of 88.2%. Relapse was predicted with a lead time interval of up to 38 months with a median of around 10.5 months ranging from 0 to 38 months. 100% of relapses were detected through ctDNA in patients with hormone receptor positive HER2 positive disease, triple negative breast cancer and hormone receptor negative HER2 positive disease.  Patients with a positive ctDNA test had a poor recurrence free survival with a hazard ratio of 52.98 with a 95% confidence interval of 18.32 to 153.2 with a statistically significant p value. Patients also had a significantly reduced overall survival if ctDNA was detected in the adjuvant setting. Multivariate models incorporating clinical pathologic variables and ctDNA status were analyzed. In this, ctDNA status remained the most significant factor associated with recurrence free survival and overall survival. Interestingly, concurrent ctDNA analyses and CA 15-3 measurements were available for 100 patients. CA 15-3 status was defined as positive and negative at the cutoff value of 30 units per milliliter. A Fisher's exact test showed a borderline statistically significant correlation between ctDNA status and CA 15-3, with a p value of 0.053. Again, multivariate analyses indicated that ctDNA was independent of CA 15-3 in predicting recurrence free survival and overall survival. Interestingly, ctDNA was not detected in 4 patients who experienced subsequent disease relapse, even with consistent and frequent sampling. Furthermore, ctDNA was detected in 5 out of 122 patients who did not have a subsequent recurrence, all being hormone receptor positive HER2 negative. These patients also had mature follow up. It is unknown if there was a change in the adjuvant treatment associated with subsequent negative tests, and follow up continues.   In summary, the study reaffirms that personalized ctDNA assays have high technical sensitivity and specificity for the identification of patients at risk for disease relapse. The test is highly predictive of recurrence in patients with breast cancer, especially with triple negative subtype where all patients had ctDNA detected prior to clinical relapse. However, for patients with hormone receptor positive breast cancer, these results suggest that this test needs to be used with caution, as a small proportion of patients experience disease relapse with negative tests and others whose tests are positive have not yet relapsed. It is unknown if these patients with ctDNA detected have radiographically overt metastatic disease in the absence of clinical symptoms, as concurrent radiographic surveillance was not performed in the standard of care follow up. Prospective clinical trials are required to define a role for ctDNA surveillance in clinical care.  Again, I'm Mitchell Elliot, a JCO Precision Oncology editorial fellow. Thank you for listening to the JCO Precision Oncology Article Insight, and please tune in for the next topic. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at www.asco.org/podcasts.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.      

Step into the incredible world of estrogen in our latest podcast episode. We unpack staggering statistics, explore the historical perceptions surrounding menopause, and unravel the intricate changes in women's bodies as they transition through this natural phase. From the gradual decline in egg count to the hormonal shifts that mark this milestone, we delve into the nitty-gritty details of menopause, shedding light on its far-reaching impacts beyond just the cessation of menstrual cycles. Plus hear the surprising health benefits of estrogen in men as well. Learn about: The number of women in menopause in the US Menopause from a historical perspective How our eggs are depleted with age Why many aging symptoms are inappropriately labeled as menopause symptoms The effects of estrogen loss on the heart, bones, and brain The specific changes to the vagina and bladder without estrogen How men need proper estrogen levels as well This episode is a holistic exploration of menopause, offering insights that go beyond the surface to empower understanding and discussions about this crucial life stage. Key moments in this episode are: 00:25 Menopause statistics 01:01 Were women ever expected to enter menopause?? 02:33 How women lose eggs as we age 03:54 What happens to menstrual cycles as we approach menopause 04:28 Hormone changes at menopause 06:26 Overlap of menopause symptoms as aging symptoms 06:49 Vasomotor symptoms 07:27 What happens to the heart without estrogen 10:27 What happens to our bones without estrogen 11:30 At what age women reach maximum bone mass 12:43 It's what happens after a bone fracture that is harmful 14:42 What happens to our brain without estrogen 15:36 Progestins reversing benefits of estrogen 16:36 What happens to the vagina and bladder without estrogen 19:07 What happens to men without estrogen, or with too much estrogen Learn more about the benefits of hormone optimization in men and women here: https://www.foundationsfl.com/bioidentical-hormone-optimization Here's the 2014 study showing lower cardiovascular risks in women using ERT vs those taking statins: erglind IA, Andersen M, Citarella A, Linder M, Sundström A, Kieler H. Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins. Menopause. 2015 Apr;22(4):369-76. doi: 10.1097/GME.0000000000000345. PMID: 25335101; PMCID: PMC4470525. Here's the 2012 study showing improved outcomes in women treated with HRT vs no treatment: Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Køber L, Jensen JE. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012 Oct 9;345:e6409. doi: 10.1136/bmj.e6409. PMID: 23048011. Here's the 2009 study stratifying men's cardiovascular risk based on their estradiol levels: Jankowska EA, Rozentryt P, Ponikowska B, Hartmann O, Kustrzycka-Kratochwil D, Reczuch K, Nowak J, Borodulin-Nadzieja L, Polonski L, Banasiak W, Poole-Wilson PA, Anker SD, Ponikowski P. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009 May 13;301(18):1892-901. doi: 10.1001/jama.2009.639. PMID: 19436016. And all the other studies I discussed are available as well; please message me to get the links! Follow us! Instagram @foundationskristinjacksonmd Website https://www.foundationsfl.com/ FB facebook.com/advancedurogynecology Loved this episode? Share with a friend.

Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

In this week's episode we'll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcription and hemoglobin switching. Featured Articles:Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionlet-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching Circulating Hematopoietic Stem/Progenitor Cell subsets contribute to human hematopoietic homeostasis

Circulating tumor DNA, more commonly referred to as ctDNA, has emerged as an attractive and potentially highly sensitive biomarker for patients with colorectal cancer. But what exactly is ctDNA, does it have any prognostic value for patients with colorectal liver metastasis, and how can it be incorporated into the management of said patients? In this episode from the HPB team at Behind the Knife, listen in on the discussion about ctDNA and its role in the perioperative management of colorectal liver metastasis.   Hosts Anish J. Jain MD (@anishjayjain) is a T32 Research Fellow at the University of Texas MD Anderson Cancer Center within the Department of Surgical Oncology. Timothy E. Newhook MD, FACS (@timnewhook19) is an Assistant Professor within the Department of Surgical Oncology. He is also the associate program director of the HPB fellowship at the University of Texas MD Anderson Cancer Center.  Jean-Nicolas Vauthey MD, FACS (@VautheyMD) is Professor of Surgery and Chief of the HPB Section, as well as the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center Learning Objectives: -Develop an understanding of what circulating tumor DNA (ctDNA) is.  -Develop an understanding of what makes ctDNA unique from other “tumor markers” like CEA. -Develop an understanding of the prognostic value of ctDNA for colorectal liver metastasis (CRLM).  -Develop an understanding of the current role of ctDNA in the perioperative treatment of patients with CRLM. -Develop an understanding of how ctDNA can be incorporated into future treatment algorithms for patients undergoing hepatic resection for CRLM. Papers Referenced (in the order they were mentioned in the episode): 1)    Newhook TE, Overman MJ, Chun YS, et al. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023;277(5):813-820. https://pubmed.ncbi.nlm.nih.gov/35797554/ 2)    Nishioka Y, Chun YS, Overman MJ, et al. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022;234(4):474-483. https://pubmed.ncbi.nlm.nih.gov/35290266/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Join Premium! Ready for an ad-free meditation experience? Join Premium now and get every episode from ALL of our podcasts completely ad-free now! Just a few clicks makes it easy for you to listen on your favorite podcast player.  Become a PREMIUM member today by going to --> https://WomensMeditationNetwork.com/premium Close your eyes, And allow your body to settle.  PAUSE… Breathe… And bring your attention inside.  PAUSE… Notice the movement of your belly,  As you inhale and exhale. And see if you can slow it down just a bit.  PAUSE… Notice the circular motion of your breath, Entering and exiting your nose. Circulating in, And out.  In,  And out. PAUSE… Now feel your body relax, Melting a little deeper into the support beneath you.  PAUSE… And just breathe.  I release all tension and stress from my body I am at peace and my body is relaxed I trust in my body's ability to rejuvenate during sleep PAUSE… I let go of all negative thoughts and emotions I am grateful for the rest and relaxation my body is receiving I am safe and protected as I sleep PAUSE… I trust in my body's natural sleep process I am surrounded by love and positivity I am grateful for the opportunity to rest and restore my body and mind PAUSE… I wake up feeling refreshed, energized and ready for a new day I trust in my body's ability to heal itself during sleep I am calm and peaceful as I drift off to sleep PAUSE… I release any worries and stress as I fall asleep I am in a state of complete relaxation PAUSE… I am grateful for the peaceful sleep my body is receiving I allow myself to fully let go and relax I trust in the power of my body to rejuvenate during sleep PAUSE… I am surrounded by a loving energy as I sleep I am at ease and my body is at peace as I sleep I let go of all stress and worries as I allow myself to fall asleep easily PAUSE… I trust my body to find the perfect position for sleep I release any discomfort in my body and allow myself to relax I am aware of my body's needs and honor them as I sleep PAUSE… I give myself permission to rest and rejuvenate I surround myself with feelings of safety and security I choose peace and serenity as I drift off to sleep PAUSE… I give my body the gift of deep and restful sleep I am aware of my body's state and adjust accordingly for optimal sleep PAUSE… I let go of any physical pain and allow myself to sleep soundly I trust in the power of my body to repair and regenerate as I sleep I am in flow with the current of the night.  PAUSE… I am healing as I sleep.  I feel all the details of the day dissolve from me with each breath. I am deeply relaxed.  Namaste, Beautiful

Are you ready to revolutionize the way you think about money?  In this episode we delve into how our mindset and beliefs can influence our financial reality. Learn to shift your approach and manifest prosperity through powerful Law of Attraction principles. We'll also look into:  Rewriting Your Money Story: Discover how childhood and past experiences shape your financial identity and how to rewrite a narrative that supports your wealth goals. Money as Vibration: Embrace money as an energy you can attract, recognizing that the focus of your attention dictates your financial outcomes. Circulating vs. Spending:  Change your perspective on money by viewing expenditures as circulation of energy, which encourages a healthier, more abundant mindset.   And, of course, there is a Challenge at the end for you to test out the Law of Attraction principles and how they apply to your own life.   Thanks for listening. If you find this episode helpful, please share it with a friend or family member. Rating and reviewing the podcast helps us to reach a greater number of lives.  Stay in touch with us between episodes and join us in the This Life or Something Better Facebook Group.  There, we'll share bonus episodes, run challenges and provide you with some additional inspiration as you reach for your Something Better. Work with Priscilla

Adam McKible is an associate professor of English at John Jay College of Criminal Justice. He grew up in Newburgh and moved to NYC, where he met his wife Julie and started a family before moving back to the area. “We spawned then swam upstream,” he says.  Adam's new book, “Circulating Jim Crow,” examines how The Saturday Evening Post advanced a racist ideology that supressed Black modernity through dialect fiction authored by white writers. In our interview, Adam talks about his research, the major themes of this book, and the freakish popularity of black minstrelsy in the first half of the 20th century (including in Beacon). Photo credit: David Sampliner 

Today, you'll learn about the surprising effect our immune system has on our emotional health, a new discovery about the biological clock of plants, and how researchers are rediscovering the science of psychedelics. Stress & Immunity “Mount Sinai Study Shows That Circulating Immune Cells Drawn to the Brain During Stress Can Control Emotional Behaviors.” Mt. Sinai. 2024. “Major Depressive Disorder.” by Navneet Bains & Sara Abdijadid. 2023. “Circulating myeloid-derived MMP8 in stress susceptibility and depression.” by Flurin Cathomas, et al. 2024. Crop Resilience “USC researchers uncover biological circuit that protects plants from extreme conditions.” EurekAlert! 2024. “Climate Change Impacts on Agriculture and Food Supply.” EPA. 2023. “The interplay between the circadian clock and abiotic stress responses mediated by ABF3 and CCA1/LHY.” by Tong Liang, et al. 2024. Psychedelic Scale “An intriguing psychedelic assessment is back from the dead, thanks to Swiss scientists.” by Eric W. Dolan. 2024. “The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.” by Tomas Frymann, et al. 2022. “The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.” by Kurt Stocker, et al. 2023. Follow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers. Hosted on Acast. See acast.com/privacy for more information.

BUFFALO, NY- March 20, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.” In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke, Manqing Hong, Qi Zhang, Shuyuan Ma, Tina X. Chen, Janet Lai, Nitin Udar, Juan-Sebastian Saldivar, Erin Ayash, Joshua Anderson, Jiang Li, Tiange Cui, Tu Le, Ruthie Chow, Randy Jerel Velasco, Chris Mallo, Rose Santiago, Robert C. Bruce, Laurie J. Goodman, Yi Chen, Dan Norton, Richard O. Chen, and John M. Lyle from Personalis, Inc. describe the analytical validation of NeXT Personal®, an ultra-sensitive, tumor-informed circulating tumor DNA (ctDNA) assay for detecting residual disease, monitoring therapy response, and detecting recurrence in patients diagnosed with solid tumor cancers. “NeXT Personal uses whole genome sequencing of tumor and matched normal samples combined with advanced analytics to accurately identify up to ~1,800 somatic variants specific to the patient's tumor.” A personalized panel is created, targeting these variants and then used to sequence cell-free DNA extracted from patient plasma samples for ultra-sensitive detection of ctDNA. The NeXT Personal analytical validation is based on panels designed from tumor and matched normal samples from two cell lines, and from 123 patients across nine cancer types. Analytical measurements demonstrated a detection threshold of 1.67 parts per million (PPM) with a limit of detection at 95% (LOD95) of 3.45 PPM. NeXT Personal showed linearity over a range of 0.8 to 300,000 PPM (Pearson correlation coefficient = 0.9998). Precision varied from a coefficient of variation of 12.8% to 3.6% over a range of 25 to 25,000 PPM. The assay targets 99.9% specificity, with this validation study measuring 100% specificity and in silico methods giving a confidence interval of 99.92 to 100%. “In summary, this study demonstrates NeXT Personal as an ultra-sensitive, highly quantitative and robust ctDNA assay that can be used to detect residual disease, monitor treatment response, and detect recurrence in patients.” DOI - https://doi.org/10.18632/oncotarget.28565 Correspondence to - John M. Lyle - john.lyle@personalis.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28565 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, circulating tumor DNA, whole genome sequencing, molecular residual disease, tumor-informed assay, analytical validation Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Tune in to this episode of Breast Cancer Conversations as Shannon and Erin share their personal experiences with the Signatara test. Shannon, living with oligometastatic breast cancer, takes a holistic approach to her treatment plan, while Erin, with early-stage triple-negative breast cancer, offers insights from a different perspective.Personalized blood tests for cancer, such as the Signatera are revolutionizing the way we monitor and treat cancer. These tests offer a non-invasive and more accurate way to detect circulating tumor cells in the bloodstream, allowing for early detection of cancer recurrence or progression.The Signatera test, developed by Natera, uses a combination of blood samples and tissue samples to create a specialized test that can detect circulating tumor cells that may not be detectable through traditional testing methods. By analyzing the levels of these circulating tumor cells in the bloodstream, the test can provide valuable information about the presence of residual cancer cells and the risk of recurrence or progression.Discover how Signatara is used to determine treatment plans and explore a variety of perspectives on managing breast cancer.[00:07:12] Holistic cancer treatment approaches.[00:14:06] Breast cancer treatment options.[00:18:13] Pathology complete response.[00:23:19] Circulating tumor cells detection.[00:25:52] Genetic makeup of cancer cells.[00:30:36] Exploring treatment options.[00:37:31] Moments of advocacy and empowerment.[00:44:33] Customizing Cancer Treatments.[00:49:17] Early cancer detection methods.[00:50:52] Misconceptions about cancer stages.+++++++++++++++++++++Attend a free virtual SurvivingBreastCancer.org event:https://www.survivingbreastcancer.org/eventsFollow us on InstagramLaura and Will: https://www.instagram.com/laura_and_will/SurvivingBreastCancer.org: https://www.survivingbreastcancer.org/Breast Cancer Conversations: https://www.instagram.com/breastcancerconversations/About SurvivingBreastCancer.org: SurvivingBreastCancer.org, Inc. (SBC) is a federally recognized 501(c)(3) non-profit virtual platform headquartered in Boston with a national and global reach. Through education, community, and resources, SurvivingBreastCancer.org supports women and men going through breast cancer. We provide a sanctuary of strength, compassion, and empowerment, where those diagnosed with cancer unite to share their stories, learn invaluable coping strategies to manage wellness and mental health, and find solace in the unbreakable bond that fuels hope, resilience, and the courage to conquer adversity.Support the show

Dean takes all types of questions surrounding your home & about plans + permits! Dean breaks down  city's permits and its codes that include: repairs, improvements, movements, converting & demolishing. Dean shares that the International Building code is updated every three years and how new updates are still rolling through. Dean shares his knowledge on heater issues, cold air circulation and about air sealing homes.

EPISODE 106 | Suffer the Children – Pizzagate, Wayfair & the Seeds of QAnon "Without a clear indication of the author's intent, it is difficult or impossible to tell the difference between an expression of sincere extremism and a parody of extremism." In the world of the internet, this is known as Poe's Law, and it's especially applicable to the weird narrative Gordian Knot known as Pizzagate. The adage applies not just to how absurd some beliefs are, but also to the arguments made by people who hold these beliefs. First formulated in 2005 by Nathan Poe, it builds on a 2001 quote by Alan Morgan called Alan's 2nd Law of Newsgroups, which states, “Any sufficiently advanced troll is indistinguishable from a genuine kook.” And that is certainly the case for the wild story that “a hipster-heavy pizza parlor” (as they put it on their website) in the Chevy Chase neighborhood of Washington D.C. is not just a fun family place with pizza, ping pong and live music, but the nerve center for an diabolical child trafficking ring that operates out in the open because they are protected by highly-placed pedophiles in the Democratic party. As an article on Cracked.com puts it, “This is supported by lots of very stupid evidence”. The stakes of the fake narrative are so high that it's become more than just true believers review bombing the place. Workers have been harassed and, on December 4, 2016, a heavily armed man entered the restaurant and started firing guns. The story of Pizzagate is the story of how the conspirasphere went from harmless kookery to being actually, physically dangerous. TRIGGER WARNING: Some pretty disturbing things will be talked about in this episode, so if the subject of child sexual abuse and trafficking is deeply uncomfortable for you, perhaps you should not listen. I mean, it should be uncomfortable to anyone, but you know what I mean. Like what we do? Then buy us a beer or three via our page on Buy Me a Coffee. #ConspiracyClearinghouse #sharingiscaring #donations #support #buymeacoffee You can also SUBSCRIBE to this podcast. Review us here or on IMDb! SECTIONS 03:11 - A note, pedophilia is a mental disorder, victims suffer for many years, how do we handle this problem? 06:31 - How it all began: Hillary Clinton's emails, John Podesta, Anthony Weiner and Huma Abedin; "Carmen Katz" makes allegations, "David Goldberg" shares and extends these 08:46 - Side note: "Carmen Katz" is Cynthia Campbell, "David Goldberg" is an anti-Semitic fake profile; Amanda Rob finds Borce Pejcev in Macedonia, a fake news click bait ecosystem, it really all began with Doug Hagmann of Eerie, PA 12:35 - Russian hackers Fancy Bear, APT28 and Sofacy use "spear phishing " attacks 13:30 - Pedo codes on 4chan: pizza, cheese, hot dogs, dominos and handkerchief codes; Comet Ping Pong gets targeted 16:30 - DumbScribblyUnctious see all sorts of things - murals, art, logos, musical acts and more; Pizzagaters talks of aliens, the Illuminati, Satanic rituals and Arun Rao; Susan Alefantis knew a pedophile, Tony "pasta obsession" Podesta knew Dennis Hastert, another pedophile, and also collects art (including some by Rachel Rose); Amanda Kleinman (Majestic Ape) of Heavy Breathing performs at Sasha Lord's birthday party and "secret pizza" is maybe mentioned, the film "Automatic At Sea", the Clinton Foundation in Haiti, Alex Jones issues a "bulletin" 25:49 - #pizzagate soars, Comet Ping Pong gets hassled, Turkey's Erdoğan jumps on the story, InfoWars spearheads the narrative, fake images proliferate, artists and musicians also harassed, it might all have been coordinated; other businesses (especially pizza places) get targeted, like Roberta's in Brooklyn and East Side Pies in Austin, TX 30:33 - Edgar Maddison Welch storms Comet Ping Pong with guns, InfoWars apologizes, then retracts the apology; white supremacist Jack Posobiec says Welch is a crisis actor; neo-Nazi pubs the Daily Stormer, the Right Stuff and Smoloko News continue the Pizzagate narrative 35:07 - Canadian Andrew Richmond's ice cream shop Sweet Jesus gets the #PedoGate treatment 36:15 - Portland, Oregon's Voodoo Donuts gets the same treatment thanks to talentless poet VeganMikey (Michael Whelan); #donutgate starts trending, building on a previous #donutgate when Ariana Grande and Ricky Alvarez licked food at Wolfee Donuts; Big League Politics's "research organization" Pedo Takedown Crew funds a coordinated harassment campaign and expand the narrative, adding tunnels, schools, and child-smiggling submarines 41:35 - In England, recreational troll Oliver Redmond targets Paul Cheape's vape shop business 43:32 - Mattress Firm gets targeted 45:32 - Frazzledrip: a very nasty fake video (trigger warning - seriously, it's really nasty), QAnon terms "adrenochrome" and "spirit cooking" get added to the Pizzagate lexicon 47:56 - PrincessPeach1987 kicks of the Wayfair affair, the now combined Pizzagate and QAnon make a LOT of noise, it's all nonsense and yet there were real consequences for real people, iMGSRC.ru and US Army Staff Sgt. Richard Ciccarella  57:25 - Cybersteria and the very first QAnon 4chan post Music by Fanette Ronjat More Info Pedophilia defined on Psychology Today Crimes against Children Research Center Facts and Stats About Child Sexual Abuse The possible long-term effects of experiencing child sexual abuse Long-term Effects of Child Sexual Abuse and Molestation on Helping Survivors A review of the long-term effects of child sexual abuse on the National Library of Medicine website Child Molesters: A Behavioral Analysis paper Sexuality of Offenders on the Zero Abuse Project Facts About Homosexuality and Child Molestation by Gregory Herek Everything You Need To Know About Pizzagate (Is Insane) on Cracked.com Pizzagate on RationalWiki Pizzagate: A slice of fake news on Reveal Anatomy of a Fake News Scandal in Rolling Stone Anthony Weiner breaks down after he's sentenced to 21 months for sexting on ABC News How The Bizarre Conspiracy Theory Behind "Pizzagate" Was Spread on BuzzFeed How Hackers Broke Into John Podesta and Colin Powell's Gmail Accounts on Vice Comet Ping Pong - Pizzagate Summary by DumbScribblyUnctious How Pizzagate went from fake news to a real problem for a D.C. business on PolitiFact 'It's a form of addiction' - Tony Podesta's art addiction article in The Guardian Rachel Rose - Aubade: Grendel's Mother (live reading) video Pizzagate, the fake news conspiracy theory that led a gunman to DC's Comet Ping Pong, explained on Vox Pizzagate gunman recorded video for daughters, said he's standing up for children on CBS News Death threats, abuse, then a gunman: 'Pizzagate' businesses relive ordeal in The Guardian  Pizzagate: Gunman fires in restaurant at centre of conspiracy on BBC News What to Know About Pizzagate, the Fake News Story With Real Consequences in Time 'Pizzagate' gunman pleads guilty as conspiracy theorist apologizes over case Is Comet Ping Pong Pizzeria Home to a Child Abuse Ring Led by Hillary Clinton? on Snopes Dissecting the #PizzaGate Conspiracy Theories in the New York Times A Moral Panic for the Age of Trump: “Pizzagate” is the latest in a long line of child-sex-ring myths on Slate The PizzaGate Gunman's Paranoid Rescue Fantasy Comes from a Long American Tradition on Reason 'There's Nothing You Can Do': The Legacy of #Pizzagate on SPLC Secret message board drives 'pizzagate'-style harassment campaign of small businesses on NBC News When Nerds Attack - Gamergate, Elevatorgate & Sad Puppies episode Voodoo Donuts website Voodoo Doughnut Gets Sucked Into Outrageous Far-Right Conspiracy Theory on Eater Wolfee Donuts Pressing Charges Against Ariana Grande Donut-Gate on Ariana Grande fandom wiki Vegan Mikey - bad poet and troll  #Donutgate: How one Oregon donut shop became the target of online conspiracy theorists on Salon Connecting the Dots Between Donutgate and Pizzagate Man jailed for falsely branding a businessman a ‘dirty paedophile' The Great Mattress Conspiracy: Why Are There So Many Mattress Firm Stores Why Are There So Many Mattress Stores? A wildly popular conspiracy theory about why there are so many Mattress Firm stores is starting to sound less crazy Mattress Firm responds to the wild conspiracy theory about its business that people are going crazy over The Mattress Firm Conspiracy: An Analysis The Mattress Firm Money Laundering Conspiracy Theory on Snopes What Is Frazzledrip? Fake Hillary Clinton Video Builds on Pizzagate Conspiracy Theory in Newsweek Frazzledrip: Is a Hillary Clinton 'Snuff Film' Circulating on the Dark Web? on Snopes Hush Supper Club Full Frazzledrip video (WARNING) Claims that pizza listings on Etsy are selling child pornography are baseless Reddit post that kicked off Wayfair conspiracy theories Outrageously Priced Wayfair Cabinets Lead to Human Trafficking Conspiracy Kids Shipped in Armoires? The Person Who Started the Wayfair Conspiracy Speaks in Newsweek Wayfair: The false conspiracy about a furniture firm and child trafficking on BBC News Baseless Wayfair child-trafficking theory spreads online on AP The bizarre story of how internet conspiracy theorists convinced themselves Wayfair is trafficking children on CBC News A US soldier working at Mar-a-Lago uploaded photos of an underage girl to a Russian website — a closer look at the site reveals a horrific underworld A US Army soldier who worked at Trump's Mar-a-Lago resort uploaded photos of an underage girl to a Russian website, prosecutors say How a reporter found the true story behind a false story of sex trafficking Is Wayfair Trafficking Children Via Overpriced Items? on Snopes MISSING IN KANSAS: Anabel Wilson no longer missing How A QAnon Conspiracy Theory Involving A Wayfair Pillow Left A Metro Detroit Teen Struggling A girl falsely believed to be a victim of the fake Wayfair sex-trafficking ring says she had hives, lost sleep over the conspiracy theory A QAnon con: How the viral Wayfair sex trafficking lie hurt real kids Human Trafficking Rumors: Viral Stories That Do More Harm Than Good at the Polaris Project The Storm Is the New Pizzagate — Only Worse Follow us on social: Facebook Twitter Other Podcasts by Derek DeWitt DIGITAL SIGNAGE DONE RIGHT - Winner of a 2022 Gold Quill Award, 2022 Gold MarCom Award, 2021 AVA Digital Award Gold, 2021 Silver Davey Award, 2020 Communicator Award of Excellence, and on numerous top 10 podcast lists.  PRAGUE TIMES - A city is more than just a location - it's a kaleidoscope of history, places, people and trends. This podcast looks at Prague, in the center of Europe, from a number of perspectives, including what it is now, what is has been and where it's going. It's Prague THEN, Prague NOW, Prague LATER  

#edgarberlanga #danieljacobs #canelo ️️️☎️Edgar Berlanga Vs. Daniel Jacobs

Genova's new Endo+ Profile is the first of its kind in hormonal health, offering the unique ability to test saliva, blood, and urine simultaneously. This flexibility lets providers create tailored hormonal profiles that reveal insights and connections between sex hormones, thyroid function, adrenal health, melatonin rhythms, and estrogen metabolism. While creating this product, we spent years scouring the research for the most up-to-date clinical information. Some of what we found, or more importantly didn't find, calls into question what gets repeated in the echo chambers of functional medicine. Today is part 2 of our series where we challenge common doctrine in hormone testing. It's good to be humble, take a fresh look at dogmatic concepts, and rethink what we thought we knew.   Today on The Lab Report: 3:40 Reference ranges – population vs. healthy cohort 8:15 Reference ranges - comparing HRT dosages vs. actual symptoms 10:10 Making sense of urine hormone testing 12:50 Circulating hormone levels vs. tissue effects 18:15 Sex hormone binding globulin vs. free testosterone 20:15 Question of the Day What are the logistics of customizing the Endo+? Additional Resources: Endo+ Genova Connect  **PROMO CODE TheLabReport20 for 20% off your next purchase** Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week's episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don't forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. To find a qualified healthcare provider to connect you with Genova testing, or to access select products directly yourself, visit Genova Connect. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.See omnystudio.com/listener for privacy information.